D. van der Poorten

发表

Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.

G. Dore, D. Chisholm, M. Trenell, 2010, Gastroenterology.

Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease

J. Kench, D. Chisholm, A. Xu, 2009, Hepatology.

Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery

D. van der Poorten, Andrew Yang, Melin Nguyen, 2021, Scientific Reports.

Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease

M. Bulsara, D. van der Poorten, J. George, 2011, Journal of gastroenterology and hepatology.

Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer

G. Ahlenstiel, D. van der Poorten, C. Musumba, 2015, Gastroenterology research and practice.

A maxillary mass in a HBV‐cirrhotic patient

D. van der Poorten, J. George, V. Nguyen, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease.

D. van der Poorten, Vikas Gupta, X. Mah, 2015, World journal of gastroenterology.

Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?

T. Roskams, D. van der Poorten, J. George, 2013, Hepatology.

Gastric Cancer Screening in Common Variable Immunodeficiency

G. Ahlenstiel, Ming-Wei Lin, D. van der Poorten, 2018, Journal of Clinical Immunology.

Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease.

D. van der Poorten, J. George, D. Mcleod, 2012, Journal of hepatology.

The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice

D. van der Poorten, P. Katelaris, D. K. van der Poorten, 2007, Alimentary pharmacology & therapeutics.

Congenital analbuminaemia diagnosed in adulthood in an Australian family.

G. Caridi, D. van der Poorten, M. Campagnoli, 2015, Pathology.

Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients

M. Karsdal, D. van der Poorten, J. George, 2020, Journal of hepatocellular carcinoma.

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes

D. Booth, T. Berg, A. Mangia, 2016, Hepatology.

HBV vaccination and HBV infection induces HBV-specific natural killer cell memory

D. Booth, G. Ahlenstiel, D. van der Poorten, 2020, Gut.

KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B.

G. Ahlenstiel, D. van der Poorten, J. George, 2019, Journal of hepatology.

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

M. Kamm, T. Borody, C. Kelly, 2020, Gut.

Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma

T. Iseli, D. van der Poorten, J. George, 2016, PloS one.

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

Giorgio Saracco, Neeraj Bhala, N. Bhala, 2011, Hepatology.

Visceral fat: A key mediator of steatohepatitis in metabolic liver disease

J. Kench, D. Chisholm, M. Trenell, 2008, Hepatology.

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion*

T. Iseli, A. Xu, D. van der Poorten, 2015, The Journal of Biological Chemistry.

Hepatitis C virus eradication with interferon free, DAA-based therapy results in KLRG1+, hepatitis C virus-specific memory natural killer cells.

G. Ahlenstiel, D. van der Poorten, J. George, 2020, The Journal of infectious diseases.

Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma

M. Karsdal, D. Schuppan, D. van der Poorten, 2020, Hepatic oncology.

Current and novel therapies for the treatment of nonalcoholic steatohepatitis

D. van der Poorten, J. George, D. K. van der Poorten, 2007, Hepatology international.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

T. Berg, A. Mangia, J. Nattermann, 2016, Nature Communications.

Hepatitis C Virus Induces the Cannabinoid Receptor 1

D. van der Poorten, J. George, M. Douglas, 2010, PloS one.

Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.

D. van der Poorten, J. George, D. K. van der Poorten, 2008, Clinics in liver disease.

Visceral adiposity in gastrointestinal and hepatic carcinogenesis.

D. van der Poorten, J. George, L. Qiao, 2013, Cancer letters.

Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease.

D. van der Poorten, J. George, R. Vongsuvanh, 2012, Journal of hepatology.

Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation.

D. van der Poorten, H. Gurney, V. Nguyen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply:

D. Chisholm, Kerry‐Lee Milner, D. van der Poorten, 2009 .

Liver disease in adolescents: A cohort study of high‐risk individuals

D. van der Poorten, J. George, D. Kenny, 2007, Hepatology.

NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis

H. Chan, D. van der Poorten, J. George, 2013, ISRN hepatology.